A Phase I/II Trial of Combined Weekly Bortezomib (VELCADE) and Y-90-Ibritumomab Tiuxetan (Zevalin) in Patients With Relapsed or Refractory Follicular Lymphoma and Transformed Non-Hodgkin's Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Bortezomib (Primary) ; Ibritumomab tiuxetan; Rituximab
- Indications Follicular lymphoma
- Focus Adverse reactions
- 21 Sep 2018 Status changed from active, no longer recruiting to discontinued before the accrual goal was met due to slow accrual
- 15 Mar 2017 Planned End Date changed from 1 Aug 2016 to 1 Aug 2020.
- 15 Mar 2017 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2019.